BIOXCEL THERAPEUTICS

0,6608

08-ноября-24 13:45:53

15 мин. задержка

Акции

-0,0093

-1,39%

Сегодняшний диапазон

0,6530 - 0,6800

ISIN

N/A

Источник

NASDAQ

BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024

01 мар 2024 07:00:00 Источник Nasdaq GlobeNewswire
BioXcel Therapeutics Announces Termination of Proposed Public Offering

13 фев 2024 09:00:43 Источник Nasdaq GlobeNewswire
BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)

12 фев 2024 07:14:31 Источник Nasdaq GlobeNewswire
BioXcel Therapeutics Announces Proposed Public Offering

08 фев 2024 16:01:00 Источник Nasdaq GlobeNewswire
BioXcel Therapeutics Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of BXCL701 in Combination with KEYTRUDA®

06 фев 2024 07:00:00 Источник Nasdaq GlobeNewswire
BioXcel Therapeutics Announces USPTO’s Allowance of Patent Application for Method of Treating Agitation in Alzheimer’s Disease Using Oromucosal Formulations of Dexmedetomidine

05 фев 2024 07:00:00 Источник Nasdaq GlobeNewswire
BioXcel Therapeutics Hosting Virtual Neuroscience R&D Day Today

12 дек 2023 07:00:00 Источник Nasdaq GlobeNewswire
BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage Programs

11 дек 2023 07:00:00 Источник Nasdaq GlobeNewswire
BioXcel Therapeutics to Host Virtual Neuroscience R&D Day on Dec. 12, 2023

30 ноя 2023 07:00:00 Источник Nasdaq GlobeNewswire
BioXcel Therapeutics Aligns with FDA Recommendation for Phase 3 Trial for TRANQUILITY Program, Provides Update on Strategic Financing, and Reports Third Quarter 2023 Financial Results

14 ноя 2023 07:00:00 Источник Nasdaq GlobeNewswire
BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) of Adenocarcinoma Phenotype

08 ноя 2023 07:00:02 Источник Nasdaq GlobeNewswire
BioXcel Therapeutics Announces Update on NIDA-funded Trial of BXCL501 (sublingual dexmedetomidine) for Potential Treatment of Opioid Use Disorder (OUD)

06 ноя 2023 07:00:00 Источник Nasdaq GlobeNewswire
BioXcel Therapeutics to Report Third Quarter 2023 Financial Results on November 14, 2023

31 окт 2023 07:00:00 Источник Nasdaq GlobeNewswire
BioXcel Therapeutics Receives Permanent J-Code for IGALMI™ (dexmedetomidine) Sublingual Film from Centers for Medicare & Medicaid Services

30 окт 2023 07:00:00 Источник Nasdaq GlobeNewswire
BioXcel Therapeutics Announces Positive Findings from Independent Third Party Audit of Data Integrity at TRANQUILITY II Phase 3 Trial Site

25 окт 2023 07:00:00 Источник Nasdaq GlobeNewswire
BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Small Cell Neuroendocrine Prostate Cancer

10 окт 2023 07:00:00 Источник Nasdaq GlobeNewswire
BioXcel Therapeutics Provides Update on Recent Developments for Late-Stage Clinical Programs and Expansion of IP Portfolio for IGALMI™ (dexmedetomidine) Sublingual Film

04 окт 2023 07:00:00 Источник Nasdaq GlobeNewswire
BioXcel Therapeutics Reports Second Quarter 2023 Financial Results and Announces Strategic Reprioritization

14 авг 2023 07:00:01 Источник Nasdaq GlobeNewswire
BioXcel Therapeutics to Report Second Quarter 2023 Financial Results on August 14, 2023

31 июл 2023 07:00:00 Источник Nasdaq GlobeNewswire
BioXcel Therapeutics Announces Positive Topline Results From TRANQUILITY II Phase 3 Trial of BXCL501 for Acute Treatment of Alzheimer’s Disease-Related Agitation

29 июн 2023 06:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
2
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.